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Abstract 
BACKGROUND: Hyperglycemia condition in diabetes mellitus (DM) influences proinflammatory cytokine levels 
and disrupts antioxidant balances. Glycated Hemoglobin is used as a biomarker of glycemic control in DM.  
AIM: This study aimed to analyse the association between glycated Hemoglobin with the levels of serum 
proinflammatory cytokines (interleukin (IL)-6) and antioxidants (glutathione peroxidase (GPx) and glutathione 
(GSH)) in type 2 diabetes mellitus (T2DM) patients in Universitas Sumatera Utara (USU) Hospital.  
METHODS: A total of eighty-nine T2DM patients were recruited at USU Hospital. Glycated Hemoglobin levels 
were measured using routine laboratory tests at USU Hospital. The IL-6, GPx, and GSH levels were measured 
using enzyme-linked immunosorbent (ELISA) method. The statistical significance was determined using the 
Kruskal Wallis test, followed by Mann-Whitney test (p < 0.05). 
RESULTS: The mean of glycated hemoglobin (%), IL-6 (pg/ml), GPx (ng/ml), and GSH (ng/ml) levels in T2DM 
patients were 8.96 ± 2.28, 59.27 ± 16.04, 32.13 ± 12.10, and 7.42 ± 3.50, respectively. Regarding the glycated 
Hemoglobin levels, 28.09% of patients had controlled diabetes, 24.72% of patients had poorly controlled diabetes, 
and 47.19% of patients had uncontrolled diabetes. The IL-6 levels of the three study groups based on glycated 
Hemoglobin levels were related significantly (p < 0.05), but there was no statistically significant difference 
observed between the GPx and GSH levels (p > 0.05). 
CONCLUSION: The present study suggests that the glycated Hemoglobin was associated with the levels of 
serum IL-6 levels but not GPx and GSH levels in T2DM patients in USU Hospital. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is metabolic 
syndromes caused by the failure of the pancreas to 
produce sufficient amount of insulin, or the body 
cannot use insulin effectively which will increase blood 
glucose levels or hyperglycemia [1]. The prevalence 
of diabetic patients in the world in 2015 was 415 
million cases, and the number of diabetic patients is 
estimated to increase to 642 million in 2040 [2]. 
According to the data of the International Diabetes 
Federation in 2015, Indonesia ranked as the seven 
highest number of diabetic patients in the world with 
an estimated of 10 million patients [3]. 
Based on the data of the Indonesian Ministry 
of Health in 2013, the number of diabetic patients in 
North Sumatra was around 205 thousand people. 
Hence, North Sumatra ranked 8th in terms of the 
number of diabetic patients in Indonesia [4].  
Low levels of insulin in diabetic patients will 
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cause an increase in blood glucose levels 
(BGLs)/hyperglycemia. In hyperglycemia condition, 
oxidation to the glucose triggers the formation of 
reactive oxygen species (ROS). The accumulated 
ROS is the central point to an increase in oxidative 
stress [5], [6]. Continuous oxidative stress leads to 
inflammatory conditions in the cells which will 
ultimately increase the formation of proinflammatory 
cytokines. Proinflammatory cytokines, such as tumour 
necrosis factor (TNF)-α, interleukin (IL)-1, and 
interleukin (IL)-6, can induce insulin resistance by 
interfering insulin signalling. It will worsen the function 
of insulin [7]. Previous studies showed a significant 
relationship between increased risk of type 2 diabetes 
mellitus (T2DM) and increased levels of IL-6 [8], [9]. 
T2DM is the most common type of DM because 
nearly 90% of all DM cases are this type of DM [3]. IL-
6 is a pleiotropic cytokine known to be involved in the 
amplification and protection against inflammation [10].  
Also, oxidative stress in T2DM patients 
disrupts antioxidant balances in cells, such as 
superoxide dismutase (SOD), catalase, glutathione 
peroxidase (GPx), and glutathione (GSH) [6]. Past 
research reported that T2DM patients had lower levels 
of total antioxidants status (TAS), GPx, and GSH than 
the healthy group [11], [12], [13]. GPx is an 
antioxidant enzyme that has several functions such as 
detoxifying lipid peroxide and hydrogen peroxide 
(H2O2), eliminating ROS, preventing the formation of 
new free radicals, and converting free radicals that 
have been formed into less reactive molecules [12]. 
The activity of GPx requires GSH as a direct 
scavenger and co-substrate for the peroxidase 
enzyme. GSH is the main buffer in the reduction 
process of intracellular oxidation. The GPx and GSH 
antioxidants are believed to have useful benefits for 
the body, such as to prevent and repair damage 
caused by free radicals [14], [15]. 
Optimum glycemic control is required to 
control DM and prevent worsening DM disease so that 
the increased proinflammatory cytokines and 
antioxidant imbalances due to oxidative stress can be 
controlled. HbA1c (glycated Hemoglobin) is used as a 
biomarker of glycemic control in DM condition 
because it describes blood glucose levels in the last 
60-90 days. Glycemic control in T2DM used glycated 
Hemoglobin measurement which is described as 
follows: < 7.5% of glycated Hemoglobin describes 
controlled diabetes, 7-9% of glycated Hemoglobin 
describes poor diabetes control, and > 9% of glycated 
Hemoglobin describes uncontrolled diabetes [1], [16], 
[17]. Previous studies found that glycated Hemoglobin 
levels were positively correlated with cytokine levels 
[18] but negatively correlated with antioxidant levels 
[19]. Therefore, the present study aimed to analyse 
the association between glycated Hemoglobin with 
serum proinflammatory cytokine and antioxidant levels 
in patients with T2DM in Universitas Sumatera Utara 
(USU) Hospital.  
 
Methods 
 
Research participants  
A total of eighty-nine T2DM patients were 
recruited at USU Hospital from March to September 
2018. The diagnosis was made according to the 
criteria of Indonesian Endocrinology Society by 
endocrine specialists, namely: (1) blood glucose level 
was more or equal to 200 mg/dl; (2) fasting blood 
glucose level was more or equal to 126 mg/dl; (3) 
blood glucose level was more or equal to 200 mg/dl at 
2 hours after administered 75 gram of glucose in the 
glucose tolerance test; and (4) glycated hemoglobin 
was > 6.5% [16]. 
Before participating in the research, patients 
were asked to sign an informed consent form 
explaining the research purposes, procedures, risks, 
and benefits of the study. The procedures have been 
approved by the ethics committee of the Faculty of 
Medicine, University of Sumatera Utara 
(No.227/TGL/KEPK FK USU-RSUP HAM/2018) 
following the Second Declaration of Helsinki. The 
characteristics of patients including age, medication, 
duration of diabetes, smoking, pregnant, and other 
chronic illnesses were asked using questionnaires. 
Patients who had one of these characteristics were 
excluded from the study: pregnant, took vitamin 
supplements, infections (e.g. HIV, tuberculosis, 
hepatitis, malignant diseases), anemia, 
hemoglobinopathy, history of blood transfusion in the 
last 2-3 months, other conditions that might affect the 
age of erythrocytes, or impaired kidney function.  
The patients were divided into three groups 
based on the glycated Hemoglobin levels: < 7% as 
controlled T2DM patients, 7-9% as poorly controlled 
T2DM patients, and > 9% as uncontrolled T2DM 
patients. 
 
Preparation of samples 
Blood samples (5 ml) were collected for 
serum separation using standard venipuncture after 
fasting for at least 8-12 hours. The blood samples 
were centrifuged at 3000 rpm for 10 minutes. Fasting 
blood glucose (FBG) levels were measured within 2 
hours after being taken while glycated Hemoglobin 
was measured in the whole blood using the routine 
laboratory tests (Cobas 6000 analyser with 
hexokinase and immunoturbidimetric method, Roche 
Diagnostics, Switzerland) at USU Hospital. 
Furthermore, postprandial blood glucose (PBG) levels 
were measured 2 hours after the patients had meals.  
Serum samples were stored at -80° C for 
interleukin-6 (IL-6), glutathione peroxidase (GPx), and 
glutathione (GSH) measurements. IL-6, GPx, and 
GSH were measured using enzyme-linked 
immunosorbent assay (ELISA) with commercial kits 
Sari et al. Association between Glycated Hemoglobin with the Levels of Serum Proinflammatory Cytokines and Antioxidants 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
from BioLegend, USA. The levels of proinflammatory 
cytokines and antioxidants were read with a 
microplate reader at a wavelength of 450 nm. All 
measurement process of proinflammatory cytokine 
and antioxidant levels were performed at the 
Integrated Laboratory of Faculty of Medicine, USU.  
 
Statistical analysis 
Statistical Package for the Social Sciences 
(SPSS) version 22 was used for the statistical 
analysis of the data. Kolmogorov-Smirnov test was 
used to analyse the data normality. The mean 
comparison of IL-6, GPx, and GSH levels in the study 
groups based on glycated Hemoglobin was performed 
using the Kruskal Wallis test, followed with Mann-
Whitney test if the test results showed a significance 
level. The level of significance in the study was a p-
value of < 0.05. 
 
 
Results 
 
The characteristics of T2DM patients are 
shown in Table 1. 
Table 1: Clinical and biochemical characteristics of T2DM 
patients 
Characteristics N = 89 
Age (years), mean ± SD 57.77 ± 10.43 
Gender (male/ female), N (%) 52 (58.4)/37 (41.6) 
Duration of ill (years), mean ± SD 8.60 ± 3.66 
Smoker N (%) 39 (44) 
FBG (mg/dl), mean ± SD 220.83 ± 31.13 
PBG (mg/dl), mean ± SD 301.57 ± 52.90 
Glycated Hemoglobin (%) 8.96 ± 2.28 
Interleukin-6 (pg/ml), mean ± SD 59.27 ± 16.04 
Glutathione peroxidase (ng/ml), mean ± SD 32.13 ± 12.10 
Glutathione (ng/ml), mean ± SD 7.42 ± 3.50 
 
The average age of T2DM patients was 57.77 
± 10.43 years old. Based on the gender of T2DM 
patients in the study, there were more male patients 
than female patients (58.4% vs 41.6%). The average 
duration of diabetes in the study was 8.60 ± 3.66 
years. This study also found that 44% of T2DM 
patients were smokers. The average FBG (mg/dl), 
PBG (mg/dl), glycated hemoglobin (%), IL-6 (pg/ml), 
GPx (ng/ml), and GSH (ng/ml) levels in T2DM patients 
were 220.83 ± 31.13, 301.57 ± 52.90, 8.96 ± 2.28, 
59.27 ± 16.04, 32.13 ± 12.10, and 7.42 ± 3.50, 
respectively.  
The distribution of glycated Hemoglobin of 
T2DM patients can be seen in Table 2. 
Table 2: Distribution of glycated Hemoglobin of T2DM patients 
T2DM patients  
N = 89 
N (%) Glycated Hemoglobin (%) 
Mean, SD 
Controlled 25 (28.09) 6.38 ± 0.11 
Poorly controlled 22 (24.72) 8.25 ±0.09 
Uncontrolled 42 (47.19) 10.90 ±0.21 
 
In Table 2, it can be seen that regarding the 
glycated hemoglobin levels of T2DM patients, 28.09% 
of the patients were categorized as controlled 
(mean/SD = 6.38 ± 0.11), 24.72% of the patients were 
categorized as poorly controlled (mean/SD = 8.25 ± 
0.09), and 47.19% of the patients were categorized as 
uncontrolled (mean/SD = 10.90 ± 0.21).  
The comparison of age, duration of illness, 
FBG, PBG, GPx, GSH, IL-6 levels between T2DM 
patients following glycated Hemoglobin groups can be 
seen in Table 3. 
Table 3: Comparison of biochemical levels between glycated 
Hemoglobin groups in T2DM patients (Kruskal-Wallis test) 
Characteristics (Mean 
Rank) 
T2DM patients p* 
Controlled 
(N = 25) 
Poorly controlled 
(N = 22) 
Uncontrolled (N 
= 42) 
 
Age (years) 58.28 ± 1.07 50.57 ± 1.75 63.18 ± 0.96 0.206 
FBG (mg/dl) 25.00 39.00 60.00 0.001* 
PBG (mg/dl) 25.22 41.57 58.57 0.001* 
Interleukin-6 (pg/ml) 20.76 54.50 54.55 0.001* 
Glutathione peroxidase 
(ng/ml) 
44.32 54.36 40.50 0.124 
Glutathione (ng/ml) 44.54 54.09 40.51 0.135 
p* < 0.05. 
 
The FBG, PBG, and IL-6 levels in the 
uncontrolled T2DM patients were higher than the 
poorly controlled and controlled T2DM patients. The 
Kruskal-Wallis test also showed significant differences 
between the study groups (p < 0.05). Also, the GPx 
and GSH levels (ng/ml) in the controlled T2DM 
patients were lower than the poorly controlled T2DM 
patients but higher than the uncontrolled T2DM 
patients. Based on the Kruskal Wallis test, the 
association between the GPx and GSH levels with the 
three groups of T2DM patients based on glycated 
Hemoglobin levels was not significant (p > 0.05).  
The comparison of biochemical levels 
between glycated Hemoglobin groups in T2DM 
patients can be seen in Table 4.  
Table 4: Comparison of biochemical levels between glycated 
Hemoglobin groups in T2DM patients (Mann-Whitney test) 
Characteristics 
(mean rank)  
T2DM patients 
(N = 89) 
P* 
Controlled
a 
(N = 25) 
Poorly 
controlled
b 
(N = 22) 
Uncontrolled
c 
(N = 42) 
Ab Ac Bc 
FBG (mg/dl) 25.00 39.00 60.00 0.022* 0.001* 0.001* 
PBG (mg/dl) 25.22 41.57 58.57 0.013* 0.001* 0.007* 
Interleukin-6 
(pg/ml) 
20.76 54.50 54.55 0.001* 0.001* 0.899 
p* < 0.05. 
 
In Table 4, it can be seen that the Mann-
Whitney test showed significant differences in the 
FBG, PBG, and IL-6 levels between the controlled and 
poorly controlled T2DM patients (p < 0.05). Similar 
results were also found between the controlled and 
uncontrolled T2DM patients. The FBG and PBG levels 
of the two study groups (poorly controlled and 
uncontrolled T2DM) were related significantly (p < 
0.05), whereas the IL-6 levels of the poorly controlled 
and uncontrolled T2DM patients showed the opposite 
result (p > 0.05). 
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Discussion 
 
Diabetes mellitus (DM) is metabolic syndrome 
conditions with an increasing prevalence of patients 
every year in the world. Chronic DM can cause 
complications such as hypertension, cardiovascular 
disease, kidney problems, and death. The American 
Diabetes Association (ADA) recommends the 
examination of HbA1c (glycated Hemoglobin) as the 
long-term glycemic control in DM patients [1]. 
Glycated Hemoglobin describes the history of blood 
glucose control in the previous 60-90 days. The 
glycated Hemoglobin test is recognised as the gold 
standard in assessing the development of DM [20].  
In this study, the average glycated 
Hemoglobin (%) of T2DM patients was 8.96 ± 2.28 
whereas the average duration of DM in the study was 
8.60 ± 3.66 years. A long duration of DM disease may 
cause a high average of glycated Hemoglobin in the 
study. This is because chronic hyperglycemia can 
increase glycated Hemoglobin levels by about 2-3 
times [21]. 
In addition to describing a history of blood 
glucose control in DM, glycated Hemoglobin is also 
used as an indicator of prognosis in the development 
of DM complications [20]. 
The highest percentage was found in the 
uncontrolled T2DM patients with 47.19%, and the 
average glycated Hemoglobin (%) in this group was 
10.90 ± 0.21. Similar results were also found in 
Jordanian diabetic patients [22]. Several factors might 
cause uncontrolled DM, such as education level, type 
of DM drugs consumed, duration of DM, and weight 
gain [22], [23]. Moreover, age, gender, and 
occupational factors may also affect glycated 
Hemoglobin levels in patients with DM [24]. Other 
factors that can also affect controlled diabetes 
regarding glycated Hemoglobin are adherence in diet, 
physical activity, and family history of DM [1].  
Continuously increasing blood sugar levels 
can increase reactive oxygen compounds (ROS) 
through enzymatic processes, namely through 
oxidation, phosphorylation reactions, and ADPH-
Oxidase reactions. ROS compounds formed in 
hyperglycemia will trigger complications in DM 
patients through several mechanisms. ROS tends to 
be oxidised which produces some free radical 
molecules, such as anion superoxide (O2
-
), hydroxyl 
radicals (OH), and hydrogen peroxide (H2O2) [25], 
[26]. 
The increased free radicals that exceed the 
ability of cells in overcoming them will cause damage 
to various cell components. This condition leads to the 
damage of DNA, proteins, carbohydrates, lipids, and 
other macromolecules. It will also result in the 
fragmentation of proteins and lipids peroxidation and 
dysfunction of cell membranes and enzymes which 
will eventually cause cell death. The earliest known 
mechanism of cell or tissue damage due to attack by 
free radicals is lipid peroxidation. Malondialdehyde 
(MDA) is one of the results of lipid peroxidation 
formed by free radicals under hyperglycemia 
conditions [6], [27]. Previous studies have shown that 
there is a relationship between blood glucose and 
HbA1c levels with an increase in MDA [28], [29]. 
Another complication due to the increased 
ROS is the activation mechanism of Nuclear Factor-
κB (NF-κB). NF-kB is transcription factors which 
stimulate the production of proinflammatory cytokines, 
such as TNF-α and IL-1. These proinflammatory 
cytokines have autocrine and paracrine effects which 
can trigger the production of other proinflammatory 
cytokines, such as IL-6. IL-6 is secreted by T cells and 
macrophages to stimulate the body's immune 
response. A systemic proinflammatory cascade 
process occurs. IL-6 is an intermediate cytokine which 
is known to have dual functions. First, in an 
inflammatory state, the production of IL-6 will increase 
as proinflammatory cytokines. The second function is 
that IL-6 can activate other macrophage and 
neutrophil cells to produce anti-inflammatory 
cytokines. Genes that encode IL-6 (IL6, MIM # 
147620) are found on chromosomes (Chr) 7p21 in 
humans [30], [31], [32]. 
In the present study, IL-6 levels in the 
uncontrolled diabetic patients were found to be higher 
than those of the poorly controlled and controlled 
diabetic patients (p < 0.05). This study also found that 
there were significant differences in the IL-6 levels 
between the controlled and poorly controlled group, 
and between the controlled and uncontrolled group. In 
contrast, the IL-6 levels did not differ significantly 
between the poorly controlled and uncontrolled group. 
A previous study has reported a significant 
difference in the IL-6 levels between a group of 
diabetic patients and a group of healthy people [8]. 
Furthermore, there was a significant difference found 
in the IL-6 levels of the controlled and uncontrolled 
DM patients [33]. 
If the formation of ROS in diabetic patients 
exceeds the ability of cells to overcome free radicals, 
it can cause oxidative stress in the cells. Continuous 
oxidative stress leads to a decrease in antioxidant 
capacity [27]. Antioxidants are compounds that can 
neutralise free radicals produced when ROS is 
oxidised. Antioxidants have a molecular structure that 
can give its electron compounds to free radical 
molecules and can break chain reactions from free 
radicals. The body can produce antioxidants in the 
form of enzymes, such as superoxide dismutase 
(SOD), catalase, glutathione peroxidase (GPx), and 
glutathione (GSH) [6]. 
GPx levels of the controlled T2DM patients in 
this study were lower than the poorly controlled T2DM 
patients but higher than the uncontrolled T2DM 
patients although the difference was not statistically 
significant. In line with the results of this study, a past 
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study found that there was no relationship between 
the levels of GPx and glycated Hemoglobin in T2DM 
patients. The past study also reported that the GPx 
levels (U/ml) of controlled DM were lower than those 
of the uncontrolled DM (3696.25 ± 1199.61 vs 
3914.13 ± 1219.36) [34]. Similarly, another previous 
study showed no relationship between blood glucose 
levels and glycated Hemoglobin levels with GPx levels 
even though adjustments have been made to age and 
gender [35]. In contrast, a study conducted by Wong 
et al. ,(2018) found that there was a relationship 
between GPx levels in controlled DM with chronic 
kidney disease (CDK) and uncontrolled DM in CDK 
[36]. GPx is an enzymatic antioxidant which is capable 
of detoxifying hydrogen peroxide and lipid 
hydroperoxide, preventing the formation of new free 
radicals, or converting free radicals that have been 
formed into less reactive molecules. This process 
occurs using other antioxidants, such as glutathione 
(GSH) [5], [14].  
GSH plays an important role in the 
maintenance of cell survival, DNA replication, protein 
synthesis, enzyme catalysis, transport of membrane 
transduction, receptor action, metabolism and 
maturation of cells, and regulation of immune cell 
function. Both GSH and GPx can catalyse the process 
of reducing fatty hydroperoxide to alcohol and 
hydrogen peroxide to water. When catalysing the 
process, disulfide bonds from GSH will bind to form 
oxidised glutathione (GSSG), and the glutathione 
reductase (GRx) enzyme can recycle GSSG into GSH 
again by oxidising NADPH. When cells are exposed to 
oxidation stress, there will be a cumulation of GSSG, 
and the GSH/GSSG ratio will decrease [6], [15]. 
The results showed that GSH levels were 
higher in the poorly controlled T2DM patients than in 
the controlled and uncontrolled T2DM patients, but it 
was not related significantly (p > 0.05). 
The increase in GSH levels in the poorly 
controlled T2DM patients may be related to the 
increase in GPx in the poorly controlled T2DM 
patients. GSH levels were also seen to be in line with 
GPx levels in the controlled and uncontrolled T2DM 
patients. A previous study showed an increase in the 
GSH levels of T2DM patients compared to the healthy 
controlled people (6.77 ± 0.59 vs 9.78 ± 0.58 uM /mg 
of protein) [36] whereas another study showed 
different result [37]. This might occur because of 
different compensations of cells to increase the 
expression of GSH proteins to counteract oxidative 
stress/ROS [38]. 
Furthermore, the duration of DM disease can 
also determine the GSH levels of patients. In addition 
to the duration of the disease, GSH and GPx levels 
are also influenced by age. GSH and GPx levels will 
decrease in older patients as an ageing process. It 
causes older people to be more vulnerable to free 
radicals [12]. Several previous studies revealed a 
decrease in antioxidant status in plasma and serum 
samples compared to the controls based on age. The 
decrease in various antioxidants is related to the 
formation of marker compounds for oxidative stress; 
for example, an increase in lipid hydroperoxide. In 
T2DM patients aged 50-60 years, there was an 
increase in lipid peroxidation since the onset of 
diabetes [39]. This study found that the average age 
of the poorly controlled T2DM patients was 50.57 ± 
1.75 years. This result was lower than the average 
age of the controlled and uncontrolled T2DM patients 
(58.28 ± 1.07, 63.18 ± 0.96, respectively). This 
difference might have a role in the higher antioxidant 
levels of GPx and GSH in the poorly controlled 
diabetic patients than the other two groups. 
This research was the first study investigating 
the topic at USU Hospital with cross-sectional study 
design. Longitudinal design research needs to be 
done with a larger size of samples to assess all 
variables in the data using complete questionnaires. 
Data can also be obtained regarding the history of the 
drug used. 
In conclusion, this study suggests that 
glycated Hemoglobin levels were associated with the 
levels of serum IL-6 but not GPx and GSH in T2DM 
patients in Universitas Sumatera Utara (USU) 
Hospital. Future studies should be conducted using a 
longitudinal design study and a larger size of samples 
to assess all variables measured in complete 
questionnaires.  
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